Tocofersolan
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tocofersolan: From Vitamin E Deficiency in Cholestasis to Amenorrhea
One-Sentence Summary
Tocofersolan is a water-soluble vitamin E (TPGS) derivative used to supplement vitamin E deficiency in patients with chronic cholestasis. The TxGNN model predicts a possible association with Amenorrhea, but currently there are no clinical trials and no published literature supporting this direction — this is a pure AI prediction with weak mechanistic plausibility.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Vitamin E deficiency in chronic cholestasis (based on general drug background information; no formal regulatory license text available) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tocofersolan is a water-soluble vitamin E (TPGS) derivative used to correct vitamin E deficiency in patients with chronic cholestasis; its efficacy in this original indication is established, but mechanistically the evidence for applicability to amenorrhea is limited.
The original indication (hepatobiliary/nutritional — vitamin E deficiency secondary to cholestasis) and the predicted new indication (reproductive endocrine — amenorrhea) belong to distinct physiological domains with no established causal pathway between them. The knowledge-graph rationale suggests the prediction may reflect an indirect node connection between vitamin E and reproductive/endocrine metabolism rather than a direct, biologically grounded mechanism.
This low confidence is reinforced by the rest of the top-10 prediction list for this drug, which includes clearly irrelevant veterinary diseases (infectious bovine rhinotracheitis, malignant catarrh) and genetic coagulation disorders with no plausible link to vitamin E supplementation — indicating that the underlying knowledge-graph signal for tocofersolan is noisy overall and each prediction should be interpreted with caution rather than as a directional signal on its own.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Tocofersolan is not currently marketed in the EU under any authorization on record; no license data is available for this drug.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All predicted indications for tocofersolan are supported only by TxGNN model scores (Evidence Level L5) with zero clinical trials or literature, and several other top-ranked candidates in the prediction set are clearly implausible (veterinary diseases, unrelated genetic disorders), indicating low overall signal quality. In addition, a Blocking-severity data gap on regulatory label warnings prevents this candidate from entering the S1 safety review stage.
To proceed, the following is needed:
- TFDA/EU label warnings and contraindications (Blocking gap — required before any S1 safety evaluation)
- Verified mechanism of action (MOA) data from DrugBank or another authoritative source
- Clinical or preclinical evidence specifically linking tocofersolan to amenorrhea or other top-ranked candidate indications
- Confirmation of current EU/international marketing and regulatory status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.